Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorALEXANDRE, Marie
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPRAGUE, Melanie
dc.contributor.authorMCLEAN, Chelsea
dc.contributor.authorBOCKSTAL, Viki
dc.contributor.authorDOUOGUIH, Macaya
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTHIEBAUT, Rodolphe
dc.date.accessioned2024-01-09T09:02:50Z
dc.date.available2024-01-09T09:02:50Z
dc.date.issued2023-11-08
dc.identifier.issn2059-0105en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/186968
dc.description.abstractEnThe persistence of the long-term immune response induced by the heterologous Ad26.ZEBOV, MVA-BN-Filo two-dose vaccination regimen against Ebola has been investigated in several clinical trials. Longitudinal data on IgG-binding antibody concentrations were analyzed from 487 participants enrolled in six Phase I and Phase II clinical trials conducted by the EBOVAC1 and EBOVAC2 consortia. A model based on ordinary differential equations describing the dynamics of antibodies and short- and long-lived antibody-secreting cells (ASCs) was used to model the humoral response from 7 days after the second vaccination to a follow-up period of 2 years. Using a population-based approach, we first assessed the robustness of the model, which was originally estimated based on Phase I data, against all data. Then we assessed the longevity of the humoral response and identified factors that influence these dynamics. We estimated a half-life of the long-lived ASC of at least 15 years and found an influence of geographic region, sex, and age on the humoral response dynamics, with longer antibody persistence in Europeans and women and higher production of antibodies in younger participants.
dc.description.sponsorshipInitiative for the creation of a Vaccine Research Institute - ANR-10-LABX-0077en_US
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.title.enPrediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
dc.title.alternativeNPJ Vaccinesen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1038/s41541-023-00767-yen_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed37940656en_US
dc.description.sponsorshipEuropeHorizon 2020 research and innovation programmeen_US
bordeaux.journalNPJ vaccinesen_US
bordeaux.page174en_US
bordeaux.volume8en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionINRIAen_US
bordeaux.teamSISTM_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=NPJ%20vaccines&rft.date=2023-11-08&rft.volume=8&rft.issue=1&rft.spage=174&rft.epage=174&rft.eissn=2059-0105&rft.issn=2059-0105&rft.au=ALEXANDRE,%20Marie&PRAGUE,%20Melanie&MCLEAN,%20Chelsea&BOCKSTAL,%20Viki&DOUOGUIH,%20Macaya&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée